Protara Therapeutics, Inc. (FRA:1KPA)
Germany · Delayed Price · Currency is EUR 6.35
+0.05 (0.79%)
Last updated: Dec 1, 2025, 8:10 AM CET
Protara Therapeutics Company Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases.
The company’s lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids.
The company is headquartered in New York, New York.
Protara Therapeutics, Inc.
| Country | United States |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 33 |
| CEO | Jesse Shefferman |
Contact Details
Address: 345 Park Avenue South New York, Delaware 10010 United States | |
| Phone | 646 844 0337 |
| Website | protaratx.com |
Stock Details
| Ticker Symbol | 1KPA |
| Exchange | Frankfurt Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jesse Shefferman | Chief Executive Officer |
| Patrick Fabbio | Chief Financial Officer |
| Justine O’Malley | Head of Investor Relations |